UBS AM’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $58.2M | Sell |
|
|||||
|
2025
Q2 | $72.5M | Buy |
|
|||||
|
2025
Q1 | $75.3M | Buy |
|
|||||
|
2024
Q4 | $69.4M | Buy |
|
|||||
|
2024
Q3 | $61.9M | Sell |
|
|||||
|
2024
Q2 | $83.4M | Buy |
|
|||||
|
2024
Q1 | $65.1M | Sell |
|
|||||
|
2023
Q4 | $72M | Sell |
|
|||||
|
2023
Q3 | $66.9M | Sell |
|
|||||
|
2023
Q2 | $83.3M | Hold |
|
|||||
|
2023
Q1 | $83.3M | Sell |
|
|||||
|
2022
Q4 | $105M | Sell |
|
|||||
|
2022
Q3 | $108M | Sell |
|
|||||
|
2022
Q2 | $129M | Buy |
|
|||||
|
2022
Q1 | $120M | Buy |
|
|||||
|
2021
Q4 | $100M | Buy |
|
|||||
|
2021
Q3 | $84M | Sell |
|
|||||
|
2021
Q2 | $170M | Sell |
|
|||||
|
2021
Q1 | $169M | Sell |
|
|||||
|
2020
Q4 | $216M | Buy |
|
|||||
|
2020
Q3 | $153M | Buy |
|
|||||
|
2020
Q2 | $144M | Sell |
|
|||||
|
2020
Q1 | $110M | Sell |
|
|||||
|
2019
Q4 | $114M | Buy |
|
|||||
|
2019
Q3 | $77.7M | Buy |
|
|||||
|
2019
Q2 | $87M | Sell |
|
|||||
|
2019
Q1 | $104M | Sell |
|
|||||
|
2018
Q4 | $101M | Buy |
|
|||||
|
2018
Q3 | $109M | Sell |
|
|||||
|
2018
Q2 | $111M | Buy |
|
|||||
|
2018
Q1 | $93.1M | Buy |
|
|||||
|
2017
Q4 | $102M | Buy |
|
|||||
|
2017
Q3 | $98.5M | Sell |
|
|||||
|
2017
Q2 | $97.3M | Sell |
|
|||||
|
2017
Q1 | $95.5M | Buy |
|
|||||
|
2016
Q4 | $81M | Sell |
|
|||||
|
2016
Q3 | $100M | Sell |
|
|||||
|
2016
Q2 | $85.5M | Sell |
|
|||||
|
2016
Q1 | $94.7M | Buy |
|
|||||
|
2015
Q4 | $110M | Sell |
|
|||||
|
2015
Q3 | $114M | Sell |
|
|||||
|
2015
Q2 | $153M | Sell |
|
|||||
|
2015
Q1 | $160M | Buy |
|
|||||
|
2014
Q4 | $104M | Sell |
|
|||||
|
2014
Q3 | $82.7M | Buy |
|
|||||
|
2014
Q2 | $69.8M | Buy |
|
|||||
|
2014
Q1 | $75.8M | Buy |
|
|||||
|
2013
Q4 | $59.1M | Sell |
|
|||||
|
2013
Q3 | $65.6M | Buy |
|
|||||
|
2013
Q2 | $47.5M | Buy |
|